Back to Search
Start Over
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
- Source :
- Breast Cancer Research and Treatment. 146:421-427
- Publication Year :
- 2014
- Publisher :
- Springer Science and Business Media LLC, 2014.
-
Abstract
- Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.
- Subjects :
- Adult
Oncology
Heterozygote
Cancer Research
medicine.medical_specialty
Time Factors
Antineoplastic Agents, Hormonal
medicine.medical_treatment
Genes, BRCA2
Genes, BRCA1
Breast Neoplasms
Article
Contralateral breast cancer
Breast cancer
BRCA2 Mutation
Risk Factors
Internal medicine
Odds Ratio
medicine
Humans
skin and connective tissue diseases
Aged
business.industry
Case-control study
Cancer
Oophorectomy
Neoplasms, Second Primary
Odds ratio
Middle Aged
medicine.disease
Tamoxifen
Case-Control Studies
Mutation
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 15737217 and 01676806
- Volume :
- 146
- Database :
- OpenAIRE
- Journal :
- Breast Cancer Research and Treatment
- Accession number :
- edsair.doi.dedup.....ce7b5df22a2dfdec890e6aaef924df2a